Bicalutamide is approved to treat:
Prostate cancer that has metastasized (spread to other parts of the body). It is used with a type of drug called a luteinizing hormone-releasing hormone agonist.
Bicalutamide is also being studied in the treatment of other types of cancer.
*The following content is generated by AI and is for reference only.
Bicalutamide tablets are a widely prescribed non-steroidal anti-androgen medication primarily utilized in the management of prostate cancer. The drug functions by competitively blocking androgen receptors, thereby preventing testosterone and dihydrotestosterone from binding to these receptors on prostate cancer cells. Since the growth and progression of most prostate cancers are driven by androgens, inhibiting this interaction effectively slows tumor development and extends survival rates. Bicalutamide is most commonly administered as part of a combined modality treatment for metastatic or locally advanced prostate cancer, used in conjunction with a luteinizing hormone-releasing hormone (LHRH) agonist or after surgical castration. It may also be employed as monotherapy in patients who cannot tolerate LHRH agonists.
Patients initiating therapy must adhere strictly to medical supervision due to significant potential side effects. Common adverse reactions include hot flashes, gynecomastia (breast tenderness or enlargement), decreased libido, and fatigue. More seriously, Bicalutamide can cause hepatotoxicity; therefore, liver function tests are mandatory before starting treatment and periodically throughout the course of therapy. If signs of liver dysfunction, such as jaundice, dark urine, or severe abdominal pain, occur, immediate medical attention is required. Additionally, the medication should not be taken by women, particularly pregnant or breastfeeding individuals, as it can cause fetal harm.
Drug interactions are another critical consideration. Bicalutamide may interact with warfarin and other drugs metabolized by cytochrome P450 enzymes, potentially altering their efficacy or toxicity levels. Patients should inform their healthcare provider of all current medications, including over-the-counter supplements. Dosage adjustments may be necessary based on individual health status and response to treatment. While Bicalutamide offers a crucial therapeutic option for prostate cancer, its use requires careful monitoring to balance oncological benefits against potential systemic risks. Adherence to prescribed dosing schedules and regular follow-up appointments ensures optimal patient outcomes while minimizing complications associated with long-term hormonal manipulation.